Industry News
Biotechnology Industry News
Italian pharma Alfasigma has…
Italian pharma Alfasigma has penned a 125 million euros ($145 million) deal for the rights to an injectable form of an investigational HSV encephalitis treatment.
Hopes were high Wednesday for a…
Hopes were high Wednesday for a billion-dollar megadeal—the kind the J.P. Morgan Healthcare Conference is known for—but no major deals ever materialized.
With a White House drug pricing…
With a White House drug pricing deal done and dusted and the threat of tariffs ameliorated, Sanofi is now enjoying more clarity from the federal government than at the same time last year. But several
Caldera has burst onto the scene…
Caldera has burst onto the scene with $112.5 million in combined series A cash the Massachusetts biotech will use to fund development of an inflammatory bowel disease drug licensed from China.
The Novo Nordisk Foundation is…
The Novo Nordisk Foundation is investing 5.5 billion Danish kroner in the BioInnovation Institute to help scale up more homegrown biotechs and deep tech companies.
Still riding the high of last…
Still riding the high of last year’s twice-yearly HIV PrEP approval of lenacapavir as Yeztugo, Gilead Sciences is approaching deal-making from a “position of strength” as a more mature biopharma, CEO Daniel O’Day told journalists
The twisting journey of Pretzel…
The twisting journey of Pretzel Therapeutics’ top brass appears to have come full circle, with the biotech subsuming the very company where some of its senior figures once worked.
The J.P. Morgan Healthcare…
The J.P. Morgan Healthcare Conference is rolling on Tuesday with many more conference-related events on the docket, including the start of Fierce JPM Week. Our reporters and editors are on the ground in San Francisco
Lyra Therapeutics is abandoning…
Lyra Therapeutics is abandoning work on its rhinosinusitis treatment and laying off its remaining employees.
Gary Gibbons, M.D., is retiring as…
Gary Gibbons, M.D., is retiring as National Heart, Lung and Blood Institute director, adding to the extensive churn at the top of the National Institutes of Health. The departure will mean 15 of the NIH’s
SAN FRANCISCO—The deal-hungry…
SAN FRANCISCO—The deal-hungry Danish pharma is largely sticking to its metabolic roots as it seeks out new innovation to bring into its drug development machine.
It’s been a subdued—albeit…
It’s been a subdued—albeit sunny—start to healthcare’s biggest conference in San Francisco. For Takeda's R&D head Andy Plump, M.D., Ph.D., the slower pace of the annual J.P. Morgan Healthcare Conference has been offset by the industry's
AbbVie has made no secret of the…
AbbVie has made no secret of the fact that it's taken an interest in the hotly contested PD-1xVEGF bispecific space. Now, the Big Pharma has paid $650 million to make its ambitions in this arena
A phase 3 rheumatoid arthritis…
A phase 3 rheumatoid arthritis trial of Lynk Pharmaceuticals’ JAK1 inhibitor has hit its primary endpoint, boosting the prospects of a candidate designed to avoid the adverse events caused by existing drugs.
Novartis’ continuing search for…
Novartis’ continuing search for new ways to take drugs into the brain has resulted in a $1.7 billion deal with SciNeuro Pharmaceuticals.
Teva has penned a second pact with…
Teva has penned a second pact with Royalty Pharma, this time securing up to $500 million to support the clinical development of a drug for vitiligo.
Eikon Therapeutics is planning to…
Eikon Therapeutics is planning to become the second biotech to go public in 2026 in another sign that the public markets are looking increasingly attractive to drug developers.
Eli Lilly and Nvidia, two primary…
Eli Lilly and Nvidia, two primary drivers of the recent stock market rally, are deepening their alliance to connect silicon with biology through AI-powered drug development.
The Trump administration spent…
The Trump administration spent 2025 taking a sledgehammer to science, obliterating funding and reshaping agencies like the FDA and the National Institutes of Health through layoffs and restrictive new policies. In a new letter, Noubar
The new year has ushered in a flow…
The new year has ushered in a flow of biotech-specific funds, including $700 million from Andreessen Horowitz.